Page 71 - Read Online

Rojas et al. Hepatoma Res 2018;4:31 I http://dx.doi.org/10.20517/2394-5079.2018.60 Page 15 of 17

hepatocellular carcinoma. Pathology 2012;44:318-24.
79. Mohamed NA, Swify EM, Amin NF, Soliman MM, Tag-Eldin LM, Elsherbiny NM. Is serum level of methylated RASSF1A valuable in
diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? Arab J Gastroenterol 2012;13:111-5.
80. Sun FK, Fan YC, Zhao J, Zhang F, Gao S, Zhao ZH, Sun Q, Wang K. Detection of TFPI2 methylation in the serum of hepatocellular
carcinoma patients. Dig Dis Sci 2013;58:1010-5.
81. Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N,
Carrato A, Guillen-Ponce C. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as
biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer 2015;15:797.
82. Kinugasa H, Nouso K, Miyahara K, Morimoto Y, Dohi C, Tsutsumi K, Kato H, Matsubara T, Okada H, Yamamoto K. Detection of K-ras
gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer 2015;121:2271-80.
83. Villar S, Le Roux-Goglin E, Gouas DA, Plymoth A, Ferro G, Boniol M, Lereau M, Bah E, Hall AJ, Wild CP, Mendy M, Norder H, van
der Sande M, Whittle H, Friesen MD, Groopman JD, Hainaut P. Seasonal variation in Tp53 R249S-mutated serum DNA with aflatoxin
exposure and hepatitis B virus infection. Environ Health Perspect 2011;119:1635-40.
84. Kirk GD, Lesi OA, Mendy M, Szymañska K, Whittle H, Goedert JJ, Hainaut P, Montesano R. 249ser TP53 mutation in plasma DNA,
hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 2005;24:5858-67.
85. Hosny G, Farahat N, Tayel H, Hainaut P. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with
hepatocellular carcinoma versus chronic liver diseases. Cancer Lett 2008;264:201-8.
86. Hu J, Wang Z, Fan J, Dai Z, He Y, Qiu S, Huang X, Sun J, Xiao Y, Song K, Shi Y, Sun Q, Yang X, Shi G, Yu L, Yang G, Ding Z, Gao Q,
Tang Z, Zhou J. Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after
liver transplantation. PLoS One 2011;6:e26003.
87. García-Fernández N, Macher HC, Rubio A, Jiménez-Arriscado P, Bellido-Díaz ML, Guerrero JM, Molinero P, Bernal-Bellido C, Suárez-
Artacho G, Gómez-Bravo MA. Detection of p53 mutations in circulating DNA of transplanted hepatocellular carcinoma patients as a
biomarker of tumor recurrence. Adv Exp Med Biol 2016;924:25-8.
88. Labgaa I, Villacorta-Martin C, D’Avola D, Craig AJ, von Felden J, Martins-Filho SN, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M,
Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A. A pilot study of ultra-deep targeted sequencing of
plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018; doi:10.1038/s41388-018-0206-3.
89. Chan KCA, Lai PBS, Mok TSK, Chan HLY, Ding C, Yeung SW, Lo YMD. Quantitative analysis of circulating methylated DNA as a
biomarker for hepatocellular carcinoma. Clin Chem 2008;54:1528-36.
90. Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and
prognosis of hepatocellular carcinoma. Exp Mol Pathol 2011;91:702-7.
91. Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Detecting circulating tumor DNA in hepatocellular carcinoma
patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer 2016;7:1907-14.
92. Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J,
Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X2, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O,
Guo R, Carter H, Zhu JK, Hao X, Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular
carcinoma. Nat Mater 2017;16:1155-61.
93. Chen ZZ, Huang L, Wu YH, Zhai WJ, Zhu PP, Gao YF. LncSox4 promotes the self-renewal of liver tumour-initiating cells through Stat3-
mediated Sox4 expression. Nat Commun 2016;7:12598.
94. Yuan SX, Wang J, Yang F, Tao Q fei, Zhang J, Wang L li, Yang Y, Liu H, Wang Z guang, Xu Q guo, Fan J, Liu L, Sun SH, Zhou WP. Long
noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology 2016;63:499-
511.
95. Cao C, Sun J, Zhang D, Guo X, Xie L, Li X, Wu D, Liu L. The long intergenic noncoding RNA UFC1, a target of microRNA 34a, interacts
with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells. Gastroenterology 2015;148:415-26.
96. Guo W, Liu S, Cheng Y, Lu L, Shi J, Xu G, Li N, Cheng K, Wu M, Cheng S, Liu S. ICAM-1-related noncoding RNA in cancer stem cells
maintains ICAM-1 expression in hepatocellular carcinoma. Clin Cancer Res 2016;22:2041-50.
97. Wang X, Sun W, Shen W, Xia M, Chen C, Xiang D, Ning B, Cui X, Li H, Li X, Ding J, Wang H. Long non-coding RNA DILC regulates
liver cancer stem cells via IL-6/STAT3 axis. J Hepatol 2016;64:1283-94.
98. Zhou CC, Yang F, Yuan S x. I, Ma JZ, Liu F, Yuan JH, Bi FR, Lin KY, Yin JH, Cao GW, Zhou WP, Wang F, Sun SH. Systemic genome
screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. Hepatology 2016;63:850-
63.
99. Romano G, Veneziano D, Acunzo M, Croce CM. Small non-coding RNA and cancer. Carcinogenesis 2017;38:485-91.
100. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G. Circulating microRNAs in exosomes indicate
hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012;56:1946-57.
101. Jiang L, Li X, Cheng Q, Zhang BH. Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver
disease screening. Tumour Biol 2015;36:7167-74.
102. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-83.
103. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2:569-79.
104. Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang B, Li BS, Yang SM. The emergence of long non-coding RNAs in the tumorigenesis of
hepatocellular carcinoma. Cancer Lett 2015;360:119-24.
105. Qiu MT, Hu JW, Yin R, Xu L. Long noncoding RNA: an emerging paradigm of cancer research. Tumor Biol 2013;34:613-20.
106. Lu J, Xie F, Geng L, Shen W, Sui C, Yang J. Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in
patients with hepatocellular carcinoma and HBV. Tumor Biol 2015;36:3231-6.
107. Tang J, Zhuo H, Zhang X, Jiang R, Ji J, Deng L, Qian X, Zhang F, Sun B. A novel biomarker Linc00974 interacting with KRT19 promotes
proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis 2014;5:e1549.